Co-treatment with fulv mitigated the RAD001-induced increases in P-AKTT308 and P-AKTS473, suggesting that ER is required for mTORC1 inhibitor-induced PI3K/AKT activation in endocrine-sensitive ER+ breast cancer cells (Figure 1B and Supplementary Figure 2A/2B). This evidence concerns the gene AKT1 and breast cancer.